Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5mL Under Fed Condition
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the single-dose oral bioavailability of oxcarbazepine
300 mg/5mL oral suspension of OHM Laboratories, USA (a subsidiary of Ranbaxy Pharmaceuticals
Inc.) with Trileptal® 300 mg/5mL oral suspension (containing oxcarbazepine 300 mg/5mL) of
Novartis Pharmaceutical Corporation, USA in healthy, adult, male, human subjects under fed
conditions.